Genomma Lab Internacional SAB de CV GNMLF
$0.82 $0.01 (0.76%) 1D
Last Updated: Aug 21, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
Genomma Lab Internacional SAB de CV. Stock Analysis GNMLF
United States Health Care Small Cap Genomma Lab Internacional SAB de CV engages in the development, manufacturing and marketing of pharmaceutical, beauty and personal care products. The firm is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The firm is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Genomma Lab Internacional SAB de CV (GNMLF) Chart
Financial Metrics & Statements of Genomma Lab Internacional SAB de CV (GNMLF)
FAQ's for Genomma Lab Internacional SAB de CV (GNMLF)
- As of August 2026, Genomma Lab Internacional SAB de CV GNMLF is classified as not covered according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Genomma Lab Internacional SAB de CV using these criteria to determine its compliance status.
- Muslim investors may consider investing in Genomma Lab Internacional SAB de CV if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Genomma Lab Internacional SAB de CV by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Genomma Lab Internacional SAB de CV may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Genomma Lab Internacional SAB de CV on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Genomma Lab Internacional SAB de CV (GNMLF)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
